TherapeuticsMD (TXMD) Competitors $1.30 +0.29 (+28.71%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.22 -0.09 (-6.54%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TXMD vs. OVID, NBRV, GBIO, ELYM, ICCC, FBLG, NRXP, OCX, SPRO, and ESLAShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Ovid Therapeutics (OVID), Nabriva Therapeutics (NBRV), Generation Bio (GBIO), Eliem Therapeutics (ELYM), ImmuCell (ICCC), FibroBiologics (FBLG), NRx Pharmaceuticals (NRXP), OncoCyte (OCX), Spero Therapeutics (SPRO), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Ovid Therapeutics Nabriva Therapeutics Generation Bio Eliem Therapeutics ImmuCell FibroBiologics NRx Pharmaceuticals OncoCyte Spero Therapeutics Estrella Immunopharma TherapeuticsMD (NASDAQ:TXMD) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Does the MarketBeat Community prefer TXMD or OVID? TherapeuticsMD received 31 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. However, 70.86% of users gave Ovid Therapeutics an outperform vote while only 58.57% of users gave TherapeuticsMD an outperform vote. CompanyUnderperformOutperformTherapeuticsMDOutperform Votes38658.57% Underperform Votes27341.43% Ovid TherapeuticsOutperform Votes35570.86% Underperform Votes14629.14% Is TXMD or OVID more profitable? TherapeuticsMD has a net margin of -207.77% compared to Ovid Therapeutics' net margin of -5,142.56%. TherapeuticsMD's return on equity of -14.08% beat Ovid Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD-207.77% -14.08% -9.61% Ovid Therapeutics -5,142.56%-39.24%-26.19% Do insiders & institutionals believe in TXMD or OVID? 30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, TXMD or OVID? TherapeuticsMD has higher revenue and earnings than Ovid Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$1.30M11.53-$10.28MN/AN/AOvid Therapeutics$390K112.43-$52.34M-$0.47-1.31 Which has more risk & volatility, TXMD or OVID? TherapeuticsMD has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Do analysts rate TXMD or OVID? Ovid Therapeutics has a consensus price target of $4.03, suggesting a potential upside of 553.17%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer TXMD or OVID? In the previous week, TherapeuticsMD's average media sentiment score of 0.00 beat Ovid Therapeutics' score of -0.59 indicating that TherapeuticsMD is being referred to more favorably in the media. Company Overall Sentiment TherapeuticsMD Neutral Ovid Therapeutics Negative SummaryTherapeuticsMD and Ovid Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.99M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / Sales11.53309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book0.476.747.634.64Net Income-$10.28M$138.11M$3.18B$245.69M7 Day Performance26.21%-2.43%-1.91%-2.66%1 Month Performance25.00%-1.91%-0.19%-2.15%1 Year Performance-42.48%-5.03%16.70%12.90% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.4493 of 5 stars$1.30+28.7%N/A-42.5%$14.99M$1.30M0.00420Gap UpHigh Trading VolumeOVIDOvid Therapeutics4.4252 of 5 stars$0.64-0.3%$4.03+526.5%-82.7%$45.72M$390,000.00-1.3760NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070GBIOGeneration Bio2.7689 of 5 stars$0.68flat$6.50+855.9%-69.9%$45.42M$5.90M-0.31150Gap UpELYMEliem TherapeuticsN/A$1.52-4.4%N/A-44.5%$45.22MN/A-2.879ICCCImmuCell0.1132 of 5 stars$5.05+1.0%N/A+2.4%$45.00M$17.47M-10.1070Upcoming EarningsNews CoverageFBLGFibroBiologics2.2565 of 5 stars$1.23-4.7%$13.00+956.9%-90.9%$44.78MN/A0.0010High Trading VolumeNRXPNRx Pharmaceuticals2.6717 of 5 stars$2.85-3.1%$31.67+1,011.1%-94.9%$44.75MN/A-1.332OCXOncoCyte2.4292 of 5 stars$2.56+7.6%$4.42+72.5%-13.7%$44.68M$709,000.000.00120Gap UpSPROSpero Therapeutics4.3331 of 5 stars$0.82-0.2%$5.00+513.5%-45.0%$44.43M$103.78M11.64150ESLAEstrella Immunopharma2.7645 of 5 stars$1.22+8.0%N/A+42.3%$44.14MN/A-4.69N/AAnalyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies Ovid Therapeutics Alternatives Nabriva Therapeutics Alternatives Generation Bio Alternatives Eliem Therapeutics Alternatives ImmuCell Alternatives FibroBiologics Alternatives NRx Pharmaceuticals Alternatives OncoCyte Alternatives Spero Therapeutics Alternatives Estrella Immunopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXMD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXMD Stock Alerts